<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        261-325-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CANDEPRESS 16 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Candepress 4mg, 8mg, 16mg and 32mg Tablets. The active ingredient is Candesartan Cilexetil.<br />This belongs to a group of medicines called angiotensin II receptor antagonists. It works by making your blood vessels relax and widen.<br />This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.<br />This medicine is used for:</p><ul><li>treat high blood pressure (hypertension) in adult patients and in children and adolescents aged 6 to &lt;18 years.</li><li>treating adult heart failure patients with reduced heart muscle function, in addition to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors cannot be used (ACE inhibitors are a group of medicines used to treat heart failure).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Candepress tablets if you:</strong></p><ul><li>Are <strong>allergic </strong>(hypersensitive) to Candesartan Cilexetil or any of the other ingredients of Candepress tablets (see section 6).</li><li>Are more than <strong>3 months pregnant</strong> (it is also better to avoid Candepress tablets in early pregnancy &ndash; see pregnancy section).</li><li>Have <strong>severe liver</strong> disease or <strong>biliary obstruction</strong> (a problem with the drainage of the bile from the gall bladder).</li><li>the patient is a child under 1 year of age.</li><li>you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</li></ul><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Candepress tablets.<br /><strong>Warnings and precautions</strong><br />Before you take, or whilst you are taking Candepress tablets tell your doctor if you:</p><ul><li>Have <strong>heart, liver or kidney</strong> problems, or are on <strong>dialysis</strong>.</li><li>Have recently had a <strong>kidney transplant.</strong></li><li>Are <strong>vomiting</strong>, have recently had severe <strong>vomiting</strong>, or have <strong>diarrhoea</strong>.</li><li>Have a disease of the adrenal gland called <strong>Conn&rsquo;s</strong> <strong>syndrome</strong> (also called primary <strong>hyperaldosteronism</strong>).</li><li>Have <strong>low blood</strong> <strong>pressure</strong>.</li><li>Have ever had a <strong>stroke</strong>.</li><li>You must tell your doctor if you think that you are (or might become) pregnant.</li></ul><p>Candepress tablets is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if<br />used at that stage (see pregnancy section).</p><ul><li>are taking any of the following medicines used to treat high blood pressure:&nbsp;</li></ul><p>‐ an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetesrelated kidney problems.<br />‐ aliskiren.</p><ul><li>if you are taking an ACE-inhibitor together with a medicine which belongs to the class of medicines known as mineralocorticoid receptor antagonists (MRA). These medicines are for the treatment of heart failure (see &ldquo;Other medicines and Candepress&rdquo;).</li></ul><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Candepress&rdquo;.<br />Your doctor may want to see you more often and do some tests if you have any of these conditions.<br />If you are going to have an operation, tell your doctor or dentist that you are taking Candepress tablets. This is because Candepress tablets, when combined with some anaesthetics, may cause a drop in blood pressure.</p><p><strong>Children and Adolescents</strong><br />Candepress has been studied in children.<br />For more information, talk to your doctor.<br />Candepress must not be given to children under 1 year of age due to the potential risk to the developing kidneys.<br /><strong>Other medicines and Candepress</strong><br />Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without a prescription.<br />Candepress tablets can affect the way some other medicines work and some medicines can have an effect on Candepress tablets. If you are using certain medicines, your doctor may need to do blood tests from time to time.<br />In particular, tell your doctor if you are using any of the following medicines as your doctor may need to change your dose and/or take other precautions:</p><ul><li>Other medicines to help lower your blood pressure, including beta-blockers, diazoxide and ACE inhibitors such as enalapril, captopril, lisinopril or ramipril.</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation).</li><li>Acetylsalicylic acid (if you are taking more than 3g each day) (medicine to relieve pain and inflammation).</li><li>Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood).</li><li>Heparin (a medicine for thinning the blood).</li><li>Co-trimoxazole (an antibiotic medicine) also known as trimethoprim/sulfamethoxazole.</li><li>Water tablets (diuretics).</li><li>Lithium (a medicine for mental health problems).</li><li>If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Candepress&rdquo; and &ldquo;Warnings and precautions&rdquo;).</li><li>If you are being treated with an ACEinhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptor antagonists (MRA) (for example: spironolactone, eplerenone).</li></ul><p><strong>Candepress with food, drink and alcohol</strong></p><ul><li>You can take Candepress tablets with or without food.</li><li>When you are prescribed Candepress tablets, discuss with your doctor before drinking alcohol. Alcohol may make you feel faint or dizzy.</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Pregnancy</strong><br />You must tell your doctor if you think you are (or might become) pregnant.<br />Your doctor will normally advise you to stop taking Candepress tablets before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Candepress tablets. Candepress tablets is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy<br /><strong>Breast-feeding</strong><br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Candepress tablets is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br /><strong>Driving and using machines</strong><br />Some people may feel tired or dizzy when taking Candepress tablets. If this happens to you, do not drive or use any tools or machines.<br /><strong>Important information about some of the ingredients of Candepress tablets</strong><br />Candepress tablets contain lactose which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Candepress tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. It is important to keep taking Candepress tablets every day.<br />You can take Candepress tablets with or without food.<br />Swallow the tablet with a drink of water.<br />Try to take the tablet at the same time each day. This will help you to remember to take it.<br />High blood pressure:</p><ul><li>The usual dose of Candepress tablets is 8mg once a day. Your doctor may increase this dose to 16mg once a day and further up to 32mg once a day depending on blood pressure response.</li><li>In some patients, such as those with liver problems, kidney problems or those who recently have lost body fluids, e.g., throughvomiting or diarrhoea or by using water tablets, the doctor may prescribe a lower starting dose.</li><li>Some black patients may have a reduced response to this type of medicine, when given as the only treatment, and these patients may need a higher dose.</li></ul><p><u><strong>Use in children and adolescents with high blood pressure:</strong></u><br />Children 6 to &lt;18 years of age:<br />The recommended starting dose is 4 mg once daily.<br />For patients weighing &lt; 50 kg: In some patients whose blood pressure is not adequately controlled, your doctor may decide the dose needs to be increased to a maximum of 8 mg once daily.<br />For patients weighing &ge; 50 kg: In some patients whose blood pressure is not adequately controlled, your doctor may decide the dose needs to be increased to 8 mg once daily and to 16 mg once daily.</p><p>Heart failure in adults :</p><ul><li>The recommended starting dose of Candepress tablets is 4mg once a day. Your doctor may increase your dose by doubling the dose at intervals of at least 2 weeks up to 32mg once a day. Candepress tablets can be taken together with other medicines for heart failure, and your doctor will decide which treatment is suitable for you.</li></ul><p><strong>If you take more Candepress tablets than you should</strong><br />If you take more Candepress tablets than prescribed by your doctor, contact a doctor or pharmacist immediately for advice.</p><p><br /><strong>If you forget to take Candepress tablets</strong><br />Do not take a double dose to make up for a forgotten tablet. Just take the next dose as normal.</p><p><br /><strong>If you stop taking Candepress tablets</strong><br />If you stop taking Candepress tablets, your blood pressure may increase again. Therefore do not stop taking Candepress tablets without first talking to your doctor.</p><p><br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Candepress tablets can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be.<br /><strong>Stop taking Candepress tablets and seek medical help immediately if you have any of the following allergic reactions:</strong></p><ul><li>Difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat.</li><li>Swelling of the face, lips, tongue and/ or throat, which may cause difficulties in swallowing.</li><li>Severe itching of the skin (with raised lumps).</li></ul><p>Candepress tablets may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Candepress tablets has had any effect on your blood (agranulocytosis).</p><p>Other possible side effects include:<br /><strong>Common</strong> (affects 1 to 10 users in 100)</p><ul><li>Feeling dizzy/spinning sensation.</li><li>Headache.</li><li>Respiratory infection.</li><li>Low blood pressure. This may make you feel faint or dizzy.</li><li>Changes in blood test results.</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ‐ An increased amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe you may notice tiredness,&nbsp; weakness, irregular heart beat or pins and needles.</p><ul><li>Effects on how your kidneys work, especially if you already have kidney problems or heart failure. In very rare cases, kidney failure may occur.</li></ul><p><strong>Very rare</strong> (affects less than 1 user in 10,000)</p><ul><li>Swelling of the face, lips, tongue and/or throat.</li><li>A reduction in your red or white blood cells.You may notice tiredness, an infection or a fever.</li><li>Skin rash, lumpy rash (hives).</li><li>Itching.</li><li>Back pain, pain in joints and muscles.</li><li>Changes in how your liver is working, including inflammation of the liver (hepatitis).You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms.</li><li>Nausea.</li><li>Changes in blood test results:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;‐ A reduced amount of sodium in your blood. If this is severe then you may notice weakness, lack of energy, or muscle cramps.</p><ul><li>Cough.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong><br />‐ Diarrhoea.<br />&nbsp;</p><p><strong>Additional side effects in children</strong><br />In children treated for high blood pressure, side effects appear to be similar to those seen in adults, but they happen more often. Sore throat is a very common side effect in children but not reported in adults and runny nose, fever and increased heart rate are common in children but not reported in adults.</p><p><br /><strong>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.<br />- Store below 30 &deg;C.<br />- Do not use Candepress tablets after the expiry date, which is stated on the carton and on the blister pack. The expiry date refers to the last day of that month.<br />- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Candesartan Cilexetil. Each tablet contains Candesartan Cilexetil. (Ph Eur) 4 mg, 8 mg, 16 mg or 32 mg.<br />The other ingredients are: polyvinyl alcohol, lactose (mesh 200), maize starch ,carboxymethyl cellulose calcium , Ferric oxide (red) , hydroxypropyl cellulose LF, triethyl citrate , low substituted HPC (LH-21) , colloidal anhydrous silica , magnesium stearate and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Candepress 4 mg tablets: Pink color, round shape, bi-convex tablet, de-bossed with ‘RC’ on one side and '10' on the other side.
• Candepress 8 mg tablets: Pink color, Round shape, bi-convex tablet, de-bossed with 'RC' on one side and '11'on the other side.
• Candepress 16 mg tablets: Pink color, round shape, bi-convex tablet ,de-bossed with 'RC12 'on one side and break line on the other side.
• Candepress 32 mg tablets: Pink color, round shape, bi-convex tablet , de-bossed with 'RC13 'on one side and break line on the other side.

Pack sizes: 30 Tablets (3 ALU/PVC/PVDC blisters pack of 10 tablets/ blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</strong><br />P.O.Box 442, Riyadh 11411<br />Fax: +966 11 265 0505<br />Email: contact@riyadhpharma.com<br />For any information about this medicinal product, please contact the local representative of marketing authorisation holder:<br />Saudi Arabia<br />Marketing department<br />Riyadh<br />Tel: +96611 265 0111<br />Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اسم هذا الدواء كانديبرس المادة الفعالة كانديسارتان سلكسيتيل التي تنتمي إلى مجموعة من الأدوية تسمى مضادات مستقبلات الأنجيوتنسين 2. وهو يعمل عن طريق ارخاء و توسعة الأوعية الدموية هذا يساعد على خفض ضغط الدم. كما أنه يجعل من السهل على قلبك ضخ الدم إلى جميع أجزاء الجسم</p><p>ويستخدم هذا الدواء في:</p><ul><li>علاج ارتفاع ضغط الدم في المرضى البالغين والأطفال والمراهقين الذين تتراوح أعمارهم بين 6إلى 18 سنة</li><li>علاج مرضى فشل القلب البالغين مع انخفاض وظيفة عضلة القلب، بالإضافة إلى مثبطات الإنزيم المحول للأنجيوتنسين أو عندما لايمكن استخدام مثبطات الإنزيم المحول&nbsp;للأنجيوتنسين وهي (مجموعة من الأدوية المستخدمة لعلاج قصور القلب</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أقراص كانديبرس إذا كنت:</strong></p><ul dir="rtl"><li>لديك حساسية لكانديسارتان أو أي من المكونات الأخرى للأقراص. &nbsp;</li><li>حامل لأكثر من 3 أشهر (من الأفضل تجنب أقراص كانديبرس في المرحلة المبكرة من الحمل -انظري قسم الحمل).</li><li>لديك مرض كبدي شديد أو انسداد القنوات الصفراوية (وجود مشكلة في تصريف الصفراء من المرارة).</li><li>طفل مريض يقل عمره عن سنة.</li><li>مصابًا بداء السكري أو فشل وظائف الكلى وكنت يتم علاجك بأدوية خفض ضغط الدم التي يحتوي على اليسكيرين.</li></ul><p dir="RTL">إذا لم تكن متأكدا مما إذا كان أي من هذه ينطبق عليك، تحدث إلى الطبيب أو الصيدلي قبل تناول أقراص كانديبرس.</p><p dir="RTL"><strong>التحذيرات و الاحتياطات</strong><strong> </strong></p><p dir="RTL">قبل أو أثناء تناول &nbsp;أقراص كانديبرس أخبر طبيبك إذا كنت:</p><ul dir="rtl"><li>لديك مشاكل في القلب، الكبد أو الكلى، أو كنت تؤدي غسيل الكلى.</li><li>اجريت مؤخرا عملية زرع الكلى.</li><li>لديك قيء، أو عانيت مؤخرا من قيء شديد، أو إسهال.</li><li>لديك مرض الغدة الكظرية الذي يسمى متلازمة كونز و(وتسمى أيضا فرط الألدوستيرونية الابتدائي).</li><li>لديك انخفاض في ضغط الدم.</li><li>عانيت في أي وقت مضى من سكتة دماغية.</li><li>يجب عليكي إخبار الطبيب إذا كنتي تعتقدين أنكي (أو قد تصبحين) حامل. لا ينصح بتناول أقراص كانديبرس في مرحلة مبكرة من الحمل، ويجب ألا يتم تناولها إذا كان الحمل لأكثر من 3 أشهر، لأنها قد تتسبب في ضرر جسيم لطفلك إذا ما استخدمت في تلك المرحلة (انظرى قسم الحمل).</li><li>تتناول أي من الأدوية التالية المستخدمة لعلاج ارتفاع ضغط الدم:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- مثبطات ACE (على سبيل المثال ، إنالابريل ، ليسينوبريل ، راميبريل) ، على وجه الخصوص إذا كنت تعاني من مشاكل في الكلى مرتبطة بداء السكري.</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- أليسكيرين.</p><ul dir="rtl"><li>إذا كنت تتناول مثبطات الإنزيم المحول للأنجيوتنسين مع دواء ينتمي إلى فئة الأدوية المعروفة بمضادات مستقبلات مينيرالكورتيكويد (MRA). هذه الأدوية لعلاج قصور القلب (انظر &quot;الأدوية الأخرى و كانديبرس&quot;).</li></ul><p dir="RTL">قد يقوم طبيبك بفحص وظائف الكلى وضغط الدم ومقدار الشوارد (مثل البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL">انظر أيضا المعلومات الواردة تحت عنوان &quot;لا تتناول كانديبرس&quot;.</p><p dir="RTL">طبيبك قد يريد أن يراك كثيرا للقيام ببعض الاختبارات إذا كان لديك أي من هذه الحالات.</p><p dir="RTL">إذا كنت ستخضع لعملية جراحية، أخبر طبيبك أو طبيب الأسنان أنك تتناول أقراص كانديبرس. وذلك لأن أقراص كانديبرس، عند دمجها مع بعض ادوية التخدير، قد يسبب انخفاضا في ضغط الدم.</p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">&nbsp;تمت دراسة كانديبرس في الأطفال. لمزيد من المعلومات ، تحدث مع طبيبك. لا يجب إعطاؤه للأطفال دون سن 1 سنة بسبب المخاطر المحتملة على نمو الكلى.</p><p dir="RTL"><strong>الأدوية الأخرى و كانديبرس</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تستخدم، أو قد استخدمت في الآونة الأخيرة، أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">يمكن لأقراص كانديبرس أن تؤثر على طريقة عمل بعض الأدوية الأخرى، وبعض الأدوية يمكن أن يكون لها تأثير على أقراص كانديبرس.</p><p dir="RTL">&nbsp;إذا كنت تستخدم أدوية معينة ، فإن طبيبك قد يحتاج إلى إجراء اختبارات الدم من وقت لآخر.</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك إذا كنت تستخدم أي من الأدوية التالية حيث أن الطبيب قد يحتاج لتغيير الجرعة أو الالتزام بمحاذير أخرى :</p><ul dir="rtl"><li>الأدوية الأخرى المساعدة على خفض ضغط الدم، بما في ذلك حاصرات بيتا، ديازوكسيد ومثبطات الإنزيم المحول للأنجيوتينسين مثل إنالابريل، ليسينوبريل، كابتوبريل أو راميبريل.</li><li>الأدوية المضادة للالتهابات غير الستيرويدية (المسكنات) مثل الإيبوبروفين ونابروكسين، ديكلوفيناك، السيليكوكسيب أو إتيروكوكسيب (لتخفيف الآلام والالتهابات) .</li><li>أسيتيل ساليسيليك أسيد (الأسبرين) إذا كنت تتناول أكثر من 3جم كل يوم (دواء لتخفيف الألم والالتهاب).</li><li>البوتاسيوم أو بدائل الملح التي تحتوي البوتاسيوم (الأدوية التي تزيد من كمية البوتاسيوم في الدم).</li><li>الهيبارين (دواء لترقيق الدم).</li><li>كوترايموكسازول (مضاد حيوي) يعرف باسم ترايميثوبريم / سلفاموكسازول .</li><li>أقراص الماء (مدرات البول).</li><li>ليثيوم (دواء لاضطرابات الصحة العقلية).</li><li>إذا كنت تتناول مثبطات الإنزيم المحول للأنجيوتنسين أو اليكسيرين (انظر أيضًا المعلومات الموجودة تحت العناوين &quot;لا تتناول كانديبرس&quot; و &quot;التحذيرات والاحتياطات&quot;).</li><li>إذا ﺗﻢ ﻋﻼﺟﻚ ﺑﻤﺜﺒﻂ ACE ﻣﻊ ﺑﻌﺾ اﻷدوﻳﺔ اﻷﺧﺮى التي &nbsp;تعالج فشل اﻟﻘﻠﺐ اﻟﺨﺎص ﺑﻚ ، واﻟﺬي ﻳُﻌﺮف ﺑﺎﺳﻢ ﻣﻀﺎدات ﻣﺴﺘﻘﺒﻼت مينيرالكورتيكويد (MRA) (ﻋﻠﻰ ﺳﺒﻴﻞ اﻟﻤﺜﺎل: سبيرونولاكتون، ايبليرينون).</li></ul><p dir="RTL"><strong>تناول كانديبرس مع الطعام أو الشراب</strong><strong> </strong><strong>أو الكحول</strong></p><ul dir="rtl"><li>يمكنك تناول أقراص كانديبرس مع أو بدون الطعام.</li><li>عندما يتم إعطاؤك أقراص كانديبرس تناقش مع الطبيب قبل شرب الكحول. قد يجعلك الكحول تشعر بالدوار أو الاغماء.</li></ul><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">اسألي الطبيب أو الصيدلي للحصول على المشورة قبل استعمال أي دواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب عليكي إخبار الطبيب إذا كنتي تعتقدين أنكي (أو قد تصبحين) حامل. سيطلب الطبيب منكي عادة التوقف عن تناول أقراص كانديبرس قبل أن تصبحي حاملا أو في أقرب وقت من العلم أنكي حاملا، وسوف ينصح بان تتناولي دواء آخر بدلا من أقراص كانديبرس. &nbsp;لا ينصح بتناول أقراص كانديبرس في مرحلة مبكرة من الحمل، ويجب ألا يتم تناوله إذا كان الحمل لأكثر من 3 أشهر، لأنها قد تتسبب في ضرر جسيم لطفلك إذا ما استخدمت بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنتي تقومين بالرضاعة الطبيعية أو على وشك أن تبدأي الرضاعة الطبيعية. لا ينصح بتناول أقراص كانديبرس للأمهات اللواتي يقمن بالرضاعة الطبيعية، والطبيب قد يختار علاج آخر بالنسبة لكي إذا كنتي ترغبين في الرضاعة الطبيعية، وخاصة إذا كان طفلك حديث الولادة، أو ولد قبل الأوان.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">بعض الناس قد يشعرون بالتعب أو بالدوار عندما يتناولون أقراص كانديبرس. إذا كان هذا يحدث لك، لا تقود سيارة أو تستخدم أي أدوات أو آلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض العناصر في أقراص</strong><strong> </strong><strong>كانديبرس</strong></p><p dir="RTL">أقراص كانديبرس تحتوي على اللاكتوز وهو نوع من السكر. إذا قيل لك من قبل الطبيب أن لديك عدم تحمل لبعض السكريات، اتصل بالطبيب قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول أقراص كانديبرس تماما كما قال لك طبيبك. يجب أن تتحقق من الطبيب أو الصيدلي إذا كنت غير متأكد. من المهم الحفاظ على تناول أقراص كانديبرس كل يوم</p><p>يمكنك أن تتناول أقراص كانديبرس مع أو بدون الطعام</p><p>ابتلع القرص مع الماء. حاول أن تتناول القرص في نفس الوقت كل يوم. هذا سيساعدك على أن تتذكر أن تتناوله</p><p>ارتفاع ضغط الدم:</p><ul><li>الجرعة المعتادة من أقراص كانديبرس هي 8 ملجم مرة واحدة يوميا. طبيبك قد يزيد هذه الجرعة إلى 16 ملجم مرة واحدة في اليوم، والزيادة تصل إلى 32 ملجم مرة واحدة- يوميا&nbsp;اعتمادا على استجابة ضغط الدم</li><li>في بعض المرضى، مثل الذين يعانون من مشاكل في الكبد، مشاكل في الكلى أو أولئك الذين فقدوا مؤخرا سوائل الجسم، على سبيل المثال، من خلال القيء أو الإسهال أو باستخدام أقراص المياه (مدرات البول)، قد يصف الطبيب أقل جرعة في البداية</li><li>قد يعاني بعض المرضى السود من انخفاض الاستجابة لهذا النوع من الأدوية، عندما يعطى كعلاج فردي فقط، وهؤلاء المرضى قد يحتاجون جرعة أعلى</li></ul><p><strong><u>الاستخدام في الأطفال والمراهقين الذين يعانون من ارتفاع ضغط الدم</u></strong><strong><u>:</u></strong></p><p>الأطفال من 6 إلى 18 سنة من العمر:</p><p>الجرعة الموصى بها هي 4 ملجم مرة واحدة يومياً.</p><p>للمرضى الذين يزنون&lt; 50 كجم: في بعض المرضى الذين لا يتم التحكم في ضغط الدم لديهم بصورة كافية يمكن للطبيب أن يقرر زيادة الجرعة إلى 8 ملجم كحد أقصى مرة واحدة يوميا.</p><p>للمرضى الذين يزنون &ge; 50 كجم: في بعض المرضى الذين لا يتم التحكم في ضغط الدم لديهم بصورة كافية ، قد يقرر الطبيب زيادة الجرعة إلى 8 ملجم مرة واحدة يوميا وإلى 16 ملجم مرة واحدة يوميا.</p><p>فشل القلب:</p><ul><li>الجرعة الموصى بها لبدء العلاج بأقراص كانديبرس هي 4ملجم مرة واحدة يوميا. طبيبك قد يزيد الجرعة من خلال مضاعفة الجرعة على فترات زمنية لا تقل عن أسبوعن حتى 32ملجم مرة واحدة يوميا. يمكن تناول أقراص كانديبرس جنبا إلى جنب مع أدوية أخرى لمعالجة قصور القلب، والطبيب هو الذي سيقرر العلاج المناسب لك.</li></ul><p><strong>إذا تناولت أقراص</strong><strong> </strong><strong>كانديبرس</strong><strong> </strong><strong>أكثر مما يجب</strong></p><p>إذا تناولت أقراص كانديبرس أكثر من التي حددها الطبيب، اتصل بالطبيب أو الصيدلي فورا للحصول على المشورة</p><p><strong>إذا نسيت أن تتناول أقراص كانديبرس</strong></p><p>إذا نسيت أن تتناول أقراص كانديبرس لا تتناول جرعة مضاعفة لتعويض القرص المنسي. فقط تناول الجرعة التالية كما هو معتاد</p><p><strong>إذا توقفت عن تناول أقراص</strong><strong> </strong><strong>كانديبرس </strong></p><p>إذا توقفت عن تناول أقراص كانديبرس، قد يرتفع ضغط الدم مرة أخرى. ولذلك لا تتوقف عن تناول أقراص كانديبرس دون التحدث مع طبيبك</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، &nbsp;يمكن أن تتسبب أقراص كانديبرس في آثار جانبية، على الرغم من أنها لا تحدث للجميع. من المهم أن تكون على بينة من ماهية هذه الآثار الجانبية.</p><p dir="RTL"><strong>توقف عن تناول أقراص كانديبرس</strong><strong> </strong><strong>واطلب المساعدة الطبية على الفور إذا كان لديك أي من ردود فعل الحساسية التالية:</strong></p><ul dir="rtl"><li>صعوبات في التنفس، مع أو بدون تورم في الوجه والشفتين واللسان و / أو الحلق.</li><li>تورم في الوجه والشفتين واللسان و / أو الحلق، مما قد يتسبب في صعوبات في البلع.</li><li>حكة شديدة في الجلد.</li></ul><p dir="RTL">قد تؤدي أقراص كانديبرس إلى انخفاض في عدد خلايا الدم البيضاء. قد تسبب انخفاض مقاومتك للعدوى و قد تلاحظ التعب، العدوى أو ارتفاع في درجة الحرارة. إذا حدث هذا عليك الاتصال بالطبيب. طبيبك قد يقوم أحيانا باختبارات الدم للتحقق ما إذا كان أقراص كانديبرس لها أي تأثير على خلايا الدم (ندرة المحببات).</p><p dir="RTL">الآثار الجانبية الأخرى المحتملة تشمل ما يلي:</p><p dir="RTL"><strong>شائعة</strong> (تؤثر في 1-10 من كل100من المستخدمين)</p><ul dir="rtl"><li>الشعور بالغثيان / الشعور بالدوار.</li><li>الصداع.</li><li>عدوى الجهاز التنفسي.</li><li>ضغط الدم المنخفض. وهذا قد يجعلك تشعر بالدوار أو الاغماء.</li><li>تغييرات في نتائج فحص الدم:</li></ul><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - زيادة كمية البوتاسيوم في الدم، وخاصة إذا كان لديك بالفعل مشاكل في الكلى أو قصور في القلب. إذا كان التغير شديد قد تلاحظ الاجهاد، والضعف، وعدم انتظام ضربات القلب أو وخز ولسع.</p><ul dir="rtl"><li>التأثيرات على كيفية عمل الكليتين، وخاصة إذا كان لديك بالفعل مشاكل في الكلى أو قصور في القلب. في حالات نادرة جدا، قد يحدث الفشل الكلوي.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدا</strong> (تؤثر على أقل من مستخدم واحد من كل 10،000)</p><ul dir="rtl"><li>تورم في الوجه والشفتين واللسان و / أو الحلق.</li><li>انخفاض في خلايا الدم الحمراء أو البيضاء. قد تلاحظ التعب، وعدوى أو ارتفاع في درجة الحرارة.</li><li>الطفح الجلدي والطفح الجلدي العقدي (خلايا النحل).</li><li>الحكة.</li><li>آلام الظهر، وألم في المفاصل والعضلات.</li><li>تغيرات في كيفية عمل الكبد، بما في ذلك التهاب الكبد. قد تلاحظ التعب، واصفرار الجلد وبياض عينيك وأعراض تشبه الانفلونزا.</li><li>الغثيان.</li><li>التغييرات في نتائج فحص الدم:</li><li>نقص كمية الصوديوم في الدم. إذا كان هذا شديد قد تلاحظ ضعف ونقص الطاقة، أو التشنجات العضلية.</li><li>السعال.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير التكرار من البيانات المتاحة)</p><ul dir="rtl"><li>الإسهال</li></ul><p dir="RTL"><strong>آثار جانبية إضافية عند الأطفال</strong></p><p dir="RTL">في الأطفال الذين يتم علاجهم من ارتفاع ضغط الدم ، تبدو الآثار الجانبية مشابهة لتلك التي تظهر عند البالغين ، ولكنها تحدث في كثير من الأحيان. يعد التهاب الحلق من الآثار الجانبية الشائعة لدى الأطفال ، ولكن لا يتم الإبلاغ عنه في البالغين ، كما أن سيلان الأنف والحمى وزيادة معدل ضربات القلب أمر شائع في الأطفال ولكن لا يتم الإبلاغ عنه لدى البالغين.</p><p dir="RTL"><strong>إذا كان أي من الآثار الجانبية أصبح خطير، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول و مرأى الأطفال-&nbsp;</p><p>- يحفظ في درجة حرارة اقل من 30 درجة مئوية-</p><p>- يجب عدم تناول كانديبرس بعد تاريخ انتهاء الصلاحية المذكور على الشريط أو العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر-&nbsp;</p><p>- التخلص من الأدوية يجب أن لا يكون عن طريق مياه الصرف الصحي أو النفايات المنزليه. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبه. هذة التدابير مساعده في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي كانديسارتان سلكسيتيل. كل قرص يحتوي على 4 ملجم، 8 ملجم، 16 ملجم، أو 32 ملجم (دستور الأدوية الأوروبي) كانديسارتان سلكسيتيل كمادة فعالة</p><p>&nbsp;المواد الإضافية: كحول بوليفينيل ، لاكتوز&nbsp;نشا الذرة ، كاربوكسيميثيل سيليليوز الكالسيوم ، أوكسيد الحديد (احمر) ، هيدروكسيبروبايل سيليليوز تراي ايثيل سترات</p><p>.بديل منخفض &nbsp;، السيليكا الغروية اللامائية ، مغنيسيوم ستياريت و ماء نقي HPC (LH-21)&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني لكانديبرس ووصفه وحجم عبوته</strong></p><ul dir="rtl"><li>أقراص 4 ملجم وردية اللون محدبة من الناحيتين محفور على جانب واحد RC و10 على الجانب الآخر.</li><li>أقراص 8 ملجم وردية اللون محدبة من الناحيتين محفور على جانب واحد RC و11 على الجانب الآخر.</li><li>أقراص 16 ملجم وردية اللون محدبة من الناحيتين محفور على جانب واحد RC 12 وخط للكسر على الجانب الآخر.</li><li>أقراص 32 ملجم وردية اللون محدبة من الناحيتين محفور على جانب واحد RC 13 خط للكسر على الجانب الآخر.</li></ul><p dir="RTL"><strong>حجم العبوة 30 قرص </strong>(3 شرائط &nbsp;ALU/PVC/PVDC بالعلبة بكل منها 10 أقراص)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</strong></p><p>ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2018/ 11
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Candepress Tablets 16mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 16 mg of candesartan cilexetil.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Candepress 16mg :Pink color, round shape ,bi-convex  tablet ,de-bossed with  'RC12 'on one side and break line on the other side 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Candepress is indicated for:<br />&bull; The treatment of primary hypertension in adults.<br />&bull; The treatment of hypertension in children and adolescents aged 6 to &lt;18 years.<br />&bull; The treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction &le; 40%) when Angiotensin Converting Enzyme (ACE)-inhibitors are not tolerated or as add-on therapy to ACE-inhibitors in patients with symptomatic heart failure, despite optimal therapy, when mineralocorticoid receptor antagonists are not tolerated (see sections 4.2, 4.4, 4.5 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Posology in Hypertension</strong></u><br />The recommended initial dose and usual maintenance dose of Candepress is 8 mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily. Therapy should be adjusted according to blood pressure response.<br />Candepress may also be administered with other antihypertensive agents (see sections 4.3, 4.4, 4.5 and 5.1).<br />Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Candepress.<br /><strong>Elderly</strong><br />No initial dose adjustment is necessary in elderly patients.<br /><strong>Patients with intravascular volume depletion</strong><br />An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see section 4.4).</p><p><strong>Renal impairment</strong><br />The starting dose is 4 mg in patients with renal impairment, including patients on haemodialysis. The dose should be titrated according to response. There is limited experience in patients with very severe or endstage renal impairment (Clcreatinine &lt; 15 ml/min) (see section 4.4).<br /><strong>Hepatic impairment</strong><br />An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment. The dose may be adjusted according to response. Candepress is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3 and 5.2).<br /><strong>Black patients</strong><br />The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients.<br />Consequently, up-titration of Candepress and concomitant therapy may be more frequently needed for blood pressure control in black patients than in non-black patients (see section 5.1).<br /><strong>Paediatric population</strong><br />Children and adolescents aged 6 to &lt;18 years:<br />The recommended starting dose is 4 mg once daily.<br />&bull; For patients weighing &lt; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to a maximum of 8 mg once daily.<br />&bull; For patients weighing &ge; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to 8 mg once daily and then to 16 mg once daily if needed (see section 5.1).<br />Doses above 32 mg have not been studied in paediatric patients.<br />Most of the antihypertensive effect is attained within 4 weeks.<br />For children with possible intravascular volume depletion (e.g., patients treated with diuretics, particularly those with impaired renal function), Candepress treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see section 4.4).<br />Candepress has not been studied in children with glomerular filtration rate less than 30 ml/min/1.73m2 (see section 4.4).<br />Black paediatric patients<br />The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients (see section 5.1).<br />Children aged below 1 year to &lt;6 years<br />&bull; The safety and efficacy in children aged 1 to &lt;6 years of age has not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.<br />&bull; Candepress is contraindicated in children aged below 1 year (see section 4.3)<br /><strong>Posology in Heart Failure</strong><br />The usual recommended initial dose of Candepress is 4 mg once daily. Uptitration to the target dose of 32 mg once daily (maximum dose) or the highest tolerated dose is done by doubling the dose at intervals of at least 2 weeks (see section 4.4). Evaluation of patients with heart failure should always comprise assessment of renal function including monitoring of serum creatinine and potassium. Candepress can be administered with otherheart failure&nbsp; treatment, including ACE-inhibitors, beta-blockers, diuretics and digitalis or a combination of these medicinal products. Candepress may be co-administered with an ACE-inhibitor in patients with symptomatic heart failure despite optimal standard heart failure therapy when mineralocorticoid receptor antagonists are not tolerated. The combination of an ACE-inhibitor, a potassium-sparing diuretic and Candepress is not recommended and should be considered only after careful evaluation of the potential benefits and risks (see sections 4.4, 4.8 and 5.1).<br /><strong>Special patient populations</strong><br />No initial dose adjustment is necessary for elderly patients or in patients with intravascular volume depletion or renal impairment or mild to moderate hepatic impairment.<br />Paediatric population<br />The safety and efficacy of Candepress in children aged between birth and 18 years have not been established in the treatment of heart failure. No data are available.<br /><strong>Method of Administration</strong><br />Oral use.<br />Candepress should be taken once daily with or without food.<br />The bioavailability of candesartan is not affected by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to candesartan cilexetil or to any of the excipients listed in section 6.1.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Candepress with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR< 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</strong><br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).<br />Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see section 4.5 and 5.1). If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes, and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.<br /><strong>Renal impairment</strong><br />As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible patients treated with Candepress.<br />When Candepress is used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is limited experience in patients with very severe or end-stage renal impairment (Clcreatinine &lt;15 ml/min). In these patients Candepress should be carefully titrated with thorough monitoring of blood pressure.<br />Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Candepress, monitoring of serum creatinine and potassium is recommended.<br />Clinical trials in heart failure did not include patients with serum creatinine &gt;265 &mu;mol/l (&gt;3 mg/dl).<br /><strong>Paediatric population, including paediatric patients with renal impairment</strong><br />Candepress has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73m2 (see section 4.2).<br /><strong>Concomitant therapy with an ACE-inhibitor in heart failure</strong><br />The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when Candepress is used in combination with an ACE-inhibitor. Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and candesartan is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close<br />monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.<br /><strong>Haemodialysis</strong><br />During dialysis the blood pressure may be particularly sensitive to AT1- receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, Candepress should be carefully titrated with thorough monitoring of blood pressure in patients on haemodialysis.<br /><strong>Renal artery stenosis</strong><br />Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.<br /><strong>Kidney transplantation</strong><br />There is limited clinical evidence regarding Candepress use in patients who have undergone renal transplant.<br /><strong>Hypotension</strong><br />Hypotension may occur during treatment with Candepress in heart failure patients. It may also occur in hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics. Caution should be observed when initiating therapy and correction of hypovolemia should be attempted.<br />For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), Candepress treatment should be initiated under close medical supervision and a lower starting dose should be considered (see section 4.2).<br /><strong>Anaesthesia and surgery</strong><br />Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.<br /><strong>Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</strong><br />As with other vasodilators, special caution is indicated in patients suffering from haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.<br /><strong>Primary hyperaldosteronism</strong><br />Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting through inhibition of the reninangiotensin- aldosterone system. Therefore, the use of Candepress is not recommended in this population.<br /><strong>Hyperkalaemia</strong><br />Concomitant use of Candepress with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin, cotrimoxazole also known as trimethoprim/sulfamethoxazole) may lead to increases in serum potassium in hypertensive patients. Monitoring of potassium should be undertaken as appropriate.<br />In heart failure patients treated with Candepress, hyperkalaemia may occur.<br />Periodic monitoring of serum potassium is recommended. The combination of an ACE inhibitor, a potassiumsparing diuretic (e.g. spironolactone) and Candepress is not recommended and should be considered only after careful evaluation of the potential benefits and risks.<br /><strong>General</strong><br />In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensinaldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with other medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with AIIRAs. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.<br />The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure lowering properties, whether prescribed as an antihypertensive or prescribed for other indications.<br />Candepress contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.<br /><strong>Pregnancy</strong><br />AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />In post-menarche patients the possibility of pregnancy should be evaluated on a regular basis. Appropriate information should be given and/or action taken to prevent the risk of exposure during pregnancy (see sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril. No clinically significant pharmacokinetic interactions with these medicinal products have been identified.<br />Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of potassium should be undertaken as appropriate (see section 4.4).<br />Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors.<br />A similar effect may occur with AIIRAs. Use of candesartan with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.<br />When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt;3g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<br />As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1)</p><p>Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs.<br />Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).<br />&nbsp;</p><p><strong>Breast-feeding</strong><br />Because no information is available regarding the use of Candepress during breast-feeding, Candepress is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with Candepress.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment of Hypertension</strong><br />In controlled clinical studies adverse reactions were mild and transient. The overall incidence of adverse events showed no association with dose or age.<br />Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%).<br />In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo. By this definition, the most commonly reported adverse reactions were dizziness/vertigo, headache and respiratory infection.<br />The table below presents adverse reactions from clinical trials and postmarketing experience.<br />The frequencies used in the tables throughout section 4.8 are: very common (&ge;1/10), common (&ge;1/100, &lt;1/10),<br />uncommon (&ge;1/1,000, &lt;1/100), rare (&ge;1/10,000, &lt;1/1,000) and very rare (&lt;1/10,000):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effect</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Common</p></td><td><p>Respiratory infection</p></td></tr><tr><td><p>Blood and lymphatic system</p><p>disorders</p></td><td><p>Very rare</p></td><td><p>Leukopenia, neutropenia and</p><p>agranulocytosis</p></td></tr><tr><td><p>Metabolism and nutrition</p><p>disorders</p></td><td><p>Very rare</p></td><td><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Common</p></td><td><p>Dizziness/vertigo, headache</p></td></tr><tr><td><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td><p>Very rare</p></td><td><p>Cough</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>Very rare</p></td><td><p>Nausea</p></td></tr><tr><td><p>Not Known</p></td><td><p>Diarrhoea</p></td></tr><tr><td><p>Hepato-biliary disorders</p></td><td><p>Very rare</p></td><td><p>Increased liver enzymes,</p><p>abnormal hepatic function or</p><p>hepatitis</p></td></tr><tr><td><p>Skin and subcutaneous tissue</p><p>disorders</p></td><td><p>Very rare</p></td><td><p>Angioedema, rash, urticaria,</p><p>pruritus</p></td></tr><tr><td><p>Musculoskeletal and</p><p>connective tissue disorders</p></td><td><p>Very rare</p></td><td><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Very rare</p></td><td><p>Renal impairment, including renal</p><p>failure in susceptible patients (see</p><p>section 4.4)</p></td></tr></tbody></table><p><strong>Laboratory findings</strong><br />In general, there were no clinically important influences of Candepress on routine laboratory variables. As for other inhibitors of the reninangiotensin- aldosterone system, small decreases in haemoglobin have been seen. No routine monitoring of laboratory variables is usually necessary for patients receiving Candepress. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.<br /><strong>Paediatric population</strong><br />The safety of candesartan cilexetil was monitored in 255 hypertensive children and adolescents, aged 6 to &lt;18 years old, during a 4 week clinical efficacy study and a 1 year open label study (see section 5.1). In nearly all different system organ classes, the frequency of adverse events in children are within common/uncommon range.<br />Whilst the nature and severity of adverse events are similar to those in adults (see table above), the frequency of all adverse events are higher in children and adolescents, particularly in:<br />&bull; Headache, dizziness, and upper respiratory tract infection, are &ldquo;very common&rdquo; (ie, &ge;1/10) in children and &ldquo;common&rdquo; (&ge;1/100 to &lt;1/10) in adults<br />&bull; Cough is &ldquo;very common&rdquo; (ie, &gt;1/10) in children and &ldquo;very rare&rdquo; (&lt;1/10,000) in adults<br />&bull; Rash is &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) in children and &ldquo;very rare&rdquo; (&lt;1/10,000) in adults.<br />&bull; Hyperkalaemia, hyponatraemia and abnormal liver function are &ldquo;uncommon&rdquo; (&ge;1/1,000 to &lt;1/100) in children and &ldquo;very rare&rdquo; (&lt;1/10,000) in adults<br />&bull; Sinus arrhythmia, nasopharyngitis, pyrexia are &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) and oropharyngeal pain is &ldquo;very common&rdquo; (ie, &ge;1/10) in children but none are reported in adults. However, these are temporary and widespread childhood illnesses.<br />The overall safety profile for candesartan cilexetil in paediatric patients does not differ significantly from the safety profile in adults.<br /><strong>Treatment of Heart Failure</strong><br />The adverse experience profile of Candepress in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM clinical programme, comparing Candepress in doses up to 32 mg (n=3,803) to placebo (n=3,796), 21.0% of the candesartan cilexetil group and 16.1% of the placebo group discontinued treatment because of adverse events. The most commonly reported adverse reactions were hyperkalaemia, hypotension and renal impairment. These events were more common in patients over 70 years of age, diabetics, or subjects who received other medicinal products which affect the reninangiotensinaldosterone system, in particular an ACE inhibitor and/or spironolactone.<br />The table below presents adverse reactions from clinical trials and postmarketing experience.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Undesirable Effect</strong></p></td></tr><tr><td><p>Blood and lymphatic system</p><p>disorders</p></td><td><p>Common</p></td><td><p>Respiratory infection</p></td></tr><tr><td rowspan="2"><p>Metabolism and nutrition disorders</p></td><td><p>Common</p></td><td><p>Hyperkalemia</p></td></tr><tr><td><p>Very rare</p></td><td><p>Hyponatremia</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Very rare</p></td><td><p>Dizziness, headache</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Common</p></td><td><p>Hypotension</p></td></tr><tr><td><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td><p>Very rare</p></td><td><p>Cough</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>Very rare</p></td><td><p>Nausea</p></td></tr><tr><td><p>Not Known</p></td><td><p>Diarrhea</p></td></tr><tr><td><p>Hepato-biliary disorders</p></td><td><p>Very rare</p></td><td><p>Increased liver enzymes, abnormal</p><p>hepatic function or hepatitis</p></td></tr><tr><td><p>Skin and subcutaneous tissue</p><p>disorders</p></td><td><p>Very rare</p></td><td><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td><p>Musculoskeletal and</p><p>connective tissue disorders</p></td><td><p>Very rare</p></td><td><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>Common</p></td><td><p>Renal impairment, including renal</p><p>failure in susceptible patients (see</p><p>section 4.4)</p></td></tr></tbody></table><p>Laboratory findings<br />Hyperkalaemia and renal impairment are common in patients treated with Candepress for the indication of heart failure. Periodic monitoring of serum creatinine and potassium is recommended (see section 4.4).<br /><strong>To report any side effects</strong><br />- National Pharmacovigilance &amp;amp; Drug Safety Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil) in an adult patient recovery was uneventful.</p><p><em>Management</em></p><p>If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p>Candesartan is not removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pharmacotherapeutic group:</em></strong></p><p>Angiotensin II antagonists, plain, ATC code C09CA06.</p><p><u><em>Mechanism of action</em></u></p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensinaldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders. It also has a role in the pathogenesis of end organ hypertrophy and damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT1) receptor.</p><p><strong><em>&nbsp;Pharmacodynamic effects:</em></strong></p><p>Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active substance, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p>Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. There is no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trialscomparing candesartan with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p><strong><em>&nbsp;Clinical efficacy and safety</em></strong></p><p><strong><em>Hypertension</em></strong></p><p>In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. The antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate. There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment.</p><p>After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. With continuous treatment, most of the reduction in blood pressure with any dose is generally attained within four weeks and is sustained during long-term treatment. According to a meta-analysis, the average additional effect of a dose increase from 16 mg to 32 mg once daily was small. Taking into account the inter-individual variability, a more than average effect can be expected in some patients. Candesartan cilexetil once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between maximum and trough effects during the dosing interval.</p><p>The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension. The trough blood pressure reduction (systolic/diastolic) was 13.1 /10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0 /8.7 mmHg with losartan potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or felodipine.</p><p>Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive effect in black patients (usually a low-renin population) than in non-black patients. This is also the case for candesartan. In an open label clinical experience trial in 5,156 patients with diastolic hypertension, the blood pressure reduction during candesartan treatment was significantly less in black than non-black patients (14.4/10.3 mmHg vs 19.0/12.7 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while renal vascular resistance and filtration fraction are reduced. In a 3-month clinical study in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95%CI 15-42%).</p><p>There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.</p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and mortality were evaluated in a randomized clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on COgnition and Prognosis in the Elderly). Patients received candesartan cilexetil or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95%CI 0.75 to 1.06, p=0.19).</p><p>Two large randomised, controlled trials (ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamics properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><strong><em>Paediatric population - hypertension</em></strong></p><p>The antihypertensive effects of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two randomised, doubleblind multicentre, 4 week dose ranging studies.</p><p>In children aged 1 to &lt;6 years, 93 patients, 74% of whom had renal disease, were randomised to receive an oral dose of candesartan cilexetil suspension 0.05, 0.20 or 0.40 mg/kg once daily. The primary method of analysis was slope of the change in systolic blood pressure (SBP) as a function of dose.</p><p>SBP and diastolic blood pressure (DBP) decreased 6.0/5.2 to 12.0/11.1 mmHg from baseline across the three doses of candesartan cilexetil. However, since there was no placebo group, the true magnitude of blood pressure effect remains uncertain which makes a conclusive assessment of benefit-risk balance difficult in this age group.</p><p>In children aged 6 to &lt;17 years, 240 patients were randomised to receive either placebo or low, medium, or high doses of candesartan cilexetil in a ratio of 1: 2: 2: 2. For children who weighed &lt; 50 kg, the doses of candesartan cilexetil were 2, 8, or 16 mg once daily. In children who weighed &gt; 50 kg, the candesartan cilexetil doses were 4, 16 or 32 mg once daily. Candesartan at pooled doses reduced SiSBP by 10.2 mmHg (P&lt; 0.0001) and SiDBP (P=0.0029) by 6.6 mmHg, from the base line. In the placebo group, there was also a reduction of 3.7 mmHg in SiSBP (p=0.0074) and 1.80 mmHg for SiDBP (p=0.0992) from the baseline.</p><p>Despite the large placebo effect, all individual candesartan doses (and all doses pooled) were significantly superior to placebo. Maximum response in reduction of blood pressure in children below and above 50 kg was reached at 8 mg and 16 mg doses, respectively and the effect plateaued after that point.</p><p>Of those enrolled, 47% were black patients and 29% were female; mean age +/- SD was 12.9 +/- 2.6 years. In children aged 6 to &lt; 17 years there was a trend for a lesser effect on blood pressure in black patients compared to non-black patients.</p><p><strong><em>&nbsp;Heart Failure</em></strong></p><p>Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure, and improves symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure &ndash; Assessment of Reduction in Mortality and morbidity (CHARM) programme.</p><p>This placebo controlled, double-blind study programme in chronic heart failure (CHF) patients with NYHA functional class II to IV consisted of three separate studies: CHARM-Alternative (n=2,028) in patients with LVEF &le;40% not treated with an ACE inhibitor because of intolerance (mainly due to cough, 72%), CHARM-Added (n=2,548) in patients with LVEF &le;40% and treated with an ACE inhibitor, and CHARM-Preserved (n=3,023) in patients with LVEF &gt;40%. Patients on optimal CHF therapy at baseline were randomised to placebo or candesartan cilexetil (titrated from 4 mg or 8 mg once daily to 32 mg once daily or the highest tolerated dose,</p><p>mean dose 24 mg) and followed for a median of 37.7 months. After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg.</p><p>In CHARM-Alternative, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, hazard ratio (HR) 0.77 (95%CI: 0.67 to 0.89, p&lt;0.001). This corresponds to a relative risk reduction of 23%. Of candesartan patients 33.0% (95%CI: 30.1 to 36.0) and of placebo patients 40.0% (95%CI: 37.0 to 43.1) experienced this endpoint, absolute difference 7.0% (95%CI: 11.2 to 2.8). Fourteen patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.80 (95%CI: 0.70 to 0.92, p=0.001). Of candesartan patients 36.6% (95%CI: 33.7 to 39.7) and of placebo patients 42.7% (95%CI: 39.6 to 45.8) experienced this endpoint, absolute difference 6.0% (95%CI: 10.3 to 1.8). Both the mortality and morbidity (CHF hospitalisation) components of these composite endpoints contributed to the favourable effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.008).</p><p>In CHARM-Added, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, HR 0.85 (95%CI: 0.75 to 0.96, p=0.011). This corresponds to a relative risk reduction of 15%. Of candesartan patients 37.9% (95%CI: 35.2 to 40.6) and of placebo patients 42.3% (95%CI: 39.6 to 45.1) experienced this endpoint, absolute difference 4.4% (95%CI: 8.2 to 0.6). Twenty-three patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of allcause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.87 (95%CI: 0.78 to 0.98, p=0.021). Of candesartan patients 42.2% (95%CI: 39.5 to 45.0) and of placebo patients 46.1% (95%CI: 43.4 to 48.9) experienced this endpoint, absolute difference 3.9% (95%CI: 7.8 to 0.1). Both the mortality and morbidity components of these composite endpoints contributed to the favourable effects of candesartan.</p><p>Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.020).</p><p>In CHARM-Preserved, no statistically significant reduction was achieved in the composite endpoint of cardiovascular mortality or first CHF hospitalisation, HR 0.89 (95%CI: 0.77 to 1.03, p=0.118).</p><p>All-cause mortality was not statistically significant when examined separately in each of the three CHARM studies. However, all-cause mortality was also assessed in pooled populations, CHARM-Alternative and CHARM-Added, HR 0.88 (95%CI: 0.79 to 0.98, p=0.018) and all three studies, HR 0.91 (95%CI: 0.83 to 1.00, p=0.055).</p><p>The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medication. Candesartan was effective also in patients taking both beta-blockers and ACE inhibitors at the same time, and the benefit was obtained whether or not patients were taking ACE inhibitors at the target dose recommended by treatment guidelines.</p><p>In patients with CHF and depressed left ventricular systolic function (left ventricular ejection fraction, LVEF &le;40%), candesartan decreases systemic vascular resistance and pulmonary capillary wedge pressure, increases plasma renin activity and angiotensin II concentration, and decreases aldosterone levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption and distribution</em></strong></p><p>Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability. The estimated absolute bioavailability of the tablet is therefore 14%. The mean peak serum concentration (Cmax) is reached 3-4 hours following tablet intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration versus time curve (AUC) of candesartan is not significantly affected by food.</p><p>Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p>The bioavailability of candesartan is not affected by food.</p><p><strong><em>&nbsp;Biotransformation and elimination</em></strong></p><p>Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on <em>in vitro </em>data, no interaction would be expected to occur <em>in vivo </em>with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life of candesartan is approximately 9 hours. There is no accumulation following multiple doses.</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p><em>&nbsp;</em><strong><em>Pharmacokinetics in special populations</em></strong></p><p>In the elderly (over 65 years) Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects.</p><p>However, the blood pressure response and the incidence of adverse events are similar after a given dose of Candepress in young and elderly patients (see section 4.2).</p><p>In patients with mild to moderate renal impairment Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but t&frac12; was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal t&frac12; of candesartan was approximately doubled in patients with severe renal</p><p>impairment. The AUC of candesartan in patients undergoing haemodialysis was similar to that in patients with severe renal impairment.</p><p>In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2).</p><p>There is no experience in patients with severe hepatic impairment.</p><p><em>&nbsp;</em><strong><em>Paediatric population</em></strong></p><p>The pharmacokinetic properties of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two single dose PK studies.</p><p>In children aged 1 to &lt;6 years, 10 children weighing 10 to &lt;25 kg received a single dose of 0.2 mg/kg, oral suspension. There was no correlation between Cmax and AUC with age or weight. No clearance data has been collected; therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>In children aged 6 to &lt;17 years, 22 children received a single dose of 16 mg tablet. There was no correlation between Cmax and AUC with age. However weight seems to significantly correlate with Cmax (p=0.012) and AUC (p=0.011). No clearance data, has been collected, therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>Children &gt;6 years of age had exposure similar to adults given the same dose.</p><p>The pharmacokinetics of candesartan cilexetil have not been investigated in paediatric patients &lt;1 year of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In preclinical safety studies candesartan had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion.</p><p>Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the pharmacological action of candesartan. For therapeutic doses of candesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in body weight and heart weight. As in adult animals, these effects are considered to result from the pharmacological action of candesartan.</p><p>At the lowest dose of 10 mg/kg exposure to candesartan was between 12 and 78 times the levels found in children aged 1 to &lt;6 who received candesartan cilexetil at a dose of 0.2 mg/kg and 7 to 54 times those found in children aged 6 to &lt;17 who received candesartan cilexetil at a dose of 16 mg. As a no observed effect level was not identified in these studies, the safety margin for the effects on heart weight and the clinical relevance of the finding is unknown.</p><p>Foetotoxicity has been observed in late pregnancy (see section 4.6).</p><p>Data from <em>in vitro </em>and <em>in vivo </em>mutagenicity testing indicates that candesartan will not exert mutagenic or clastogenic activities under conditions of clinical use.</p><p>There was no evidence of carcinogenicity.</p><p>The renin-angiotensin-aldosterone system plays a critical role in kidney development <em>in utero</em>. Renin-angiotensin-aldosterone system blockade has been shown to lead to abnormal kidney development in very young mice.</p><p>Administering drugs that act directly on the renin-angiotensin-aldosterone system can alter normal renal development. Therefore, children aged less than 1 year should not receive Candepress (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>polyvinyl alcohol</p><p>lactose (mesh 200)</p><p>maize starch</p><p>carboxymethyl cellulose calcium</p><p>Ferric oxide (red)</p><p>hydroxypropyl cellulose LF</p><p>triethyl citrate</p><p>low substituted HPC (LH-21)</p><p>colloidal anhydrous silica</p><p>magnesium stearate</p><p>purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 Tablets (3 ALU/PVC/PVDC blisters pack of 10 tablets/ blister).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorization holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com   

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>